Hikari Power’s Abeona Therapeutics ABEO Stock Holding History

Hikari Power’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,124	Closed	-$360K	–	124
2018 Q3	$360K	Sell	1,124 -200	-15%	-$70.9K	0.04%	83
2018 Q2	$530K	Buy	+1,324	New	+$579K	0.06%	76
2017 Q2	–	Sell	-1,200	Closed	-$150K	–	95
2017 Q1	$150K	Buy	+1,200	New	+$155K	0.02%	66

Other funds holding ABEO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Hikari Power's ABEO Position: Q4 2018 in Review

Hikari Power sold out of Abeona Therapeutics (ABEO) in Q4 2018, closing a stake of 1,124 shares — an estimated $360K sold.

Hikari Power first reported a position in ABEO in Q1 2017 and held it in 3 quarters. The position peaked at $530K in Q2 2018. 99 funds tracked by Wall St. Rank hold ABEO as of Q4 2018.

Hikari Power reported no remaining Abeona Therapeutics position as of Q4 2018 after selling out during the quarter.
Hikari Power sold 1,124 Abeona Therapeutics shares in Q4 2018, an estimated $360K.
Hikari Power first reported a position in Abeona Therapeutics in Q1 2017 and held it in 3 quarters.
Hikari Power's Abeona Therapeutics position peaked at $530K in Q2 2018.
99 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q4 2018.

Based on Hikari Power's 13F filing for Q4 2018, filed 29 Jan 2019.